Jennifer Kay Plichta

Dr. Jennifer Kay Plichta

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2024 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
IBIsabelle Bedrosian
Isabelle Bedrosian
MSMark R. Somerfield
Mark R. Somerfield
MAMaria Isabel Achatz
Maria Isabel Achatz
JBJudy C. Boughey
Judy C. Boughey
GCGiuseppe Curigliano
Giuseppe Curigliano
MRMark E. Robson
Mark E. Robson
PURPOSE: To develop recommendations for germline mutation testing for patients with breast cancer. METHODS: An ASCO–Society of Surgical Oncology (SSO) panel convened to develop recommendations based on a systematic review and formal consensus process. RESULTS: Forty-seven articles met eligibility criteria for the germline mutation testing recommendations; 18 for the genetic counseling recommendations. RECOMMENDATIONS: BRCA1/ 2 mutation testing should be offered to all newly diagnosed patients with breast cancer ≤65 years and select patients >65 years based on personal history, family history, ancestry, or eligibility for poly(ADP-ribose) polymerase (PARP) inhibitor therapy. All patients with recurrent breast cancer who are candidates for PARP inhibitor therapy should be offered BRCA1/ 2 testing, regardless of family history. BRCA1/ 2 testing should be offered to women who develop a second primary cancer in the ipsilateral or contralateral breast. For patients with prior history of breast cancer and without active disease, testing should be offered to patients diagnosed ≤65 years and selectively in patients diagnosed after 65 years, if it will inform personal and family risk. Testing for high-penetrance cancer susceptibility genes beyond BRCA1/ 2 should be offered to those with supportive family histories; testing for moderate-penetrance genes may be offered if necessary to inform personal and family cancer risk. Patients should be provided enough pretest information for informed consent; those with pathogenic variants should receive individualized post-test counseling. Variants of uncertain significance should not impact management, and patients with such variants should be followed for reclassification. Referral to providers experienced in clinical cancer genetics may help facilitate patient selection and interpretation of expanded testing, and provide counseling of individuals without pathogenic germline variants but with significant family history. Additional information is available at www.asco.org/breast-cancer-guidelines .

1 October 2018 in Annals of Surgery
Verified
Journal Article
Closed access
OFOluwadamilola M. Fayanju
Oluwadamilola M. Fayanju
YRYi Ren
Yi Ren
STSamantha M. Thomas
Samantha M. Thomas
RGRachel A. Greenup
Rachel A. Greenup
JPJennifer Kay Plichta
Jennifer Kay Plichta
EHE. Shelley Hwang
E. Shelley Hwang
Objective: To determine whether the association between overall survival (OS) and response to neoadjuvant chemotherapy (NACT) in breast cancer patients varies with tumor subtype and anatomic extent of pathologic complete response (pCR). Background: pCR after NACT predicts improved OS in breast cancer, but it is unclear whether pCR limited to the breast or axilla is also associated with OS. Methods: Women with cT1-3/cN0-1 breast cancer diagnosed in 2010 to 2014 who underwent surgery following NACT were identified in the NCDB and divided into 4 subtypes based on reported hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status. Kaplan-Meier curves and Cox proportional hazards models were used to estimate OS. Multivariate logistic regression was used to identify factors associated with post-NACT response, defined as upstage (yp stage>clinical stage); no change (clinical stage = yp stage); overall (breast+axilla, ypT0N0), breast-only (ypT0N1/N1mic), or node-only (ypT1-3N0) pCR. Results: Of 33,162 identified patients, 20,265 experienced overall pCR (n = 6370, 19.2%), breast-only pCR (n = 494, 1.5%), node-only pCR (n = 1133, 3.4%), no stage change (n = 9641, 29.1%), or upstage (n = 2627, 7.9%). Compared with no stage change, breast-only pCR was associated with improved OS in triple-negative disease [hazard ratio = 0.58, 95% confidence interval (95% CI) = 0.37–0.89], and node-only pCR was associated with improved OS in both triple-negative (hazard ratio = 0.55,95% CI = 0.39–0.76) and HR+/HER2− disease (hazard ratio = 0.54, 95% CI = 0.33–0.89). For patients achieving overall (breast+axilla) pCR, unadjusted 5-year OS was 0.94 (95% CI = 0.93–0.95), with no difference between patients who were cN0 (hazard ratio = 0.95, 95% CI = 0.93–0.96) or cN1 (hazard ratio = 0.94, 95% CI = 0.92–0.96) at diagnosis. Conclusions: In node-positive patients, pCR limited to either the breast or axilla predicts survival for select receptor subtypes. In patients achieving pCR in both the breast and axilla, survival is driven by response to NACT rather than presenting cN stage.

25 April 2017 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
JCJessica A. Cintolo-Gonzalez
Jessica A. Cintolo-Gonzalez
DBDanielle Braun
Danielle Braun
ABAmanda L. Blackford
Amanda L. Blackford
EMEmanuele Mazzola
Emanuele Mazzola
AAAhmet Acar
Ahmet Acar
KHKevin S. Hughes
Kevin S. Hughes

1 September 2017 in Journal of the American College of Surgeons
Verified
Journal Article
Closed access
BSBarbara L. Smith
Barbara L. Smith
RTRong Tang
Rong Tang
URUpahvan Rai
Upahvan Rai
JPJennifer Kay Plichta
Jennifer Kay Plichta
ACAmy S. Colwell
Amy S. Colwell
SCSuzanne B. Coopey
Suzanne B. Coopey
BACKGROUND: Nipple-sparing mastectomy (NSM) has gained popularity for breast cancer treatment and prevention. There are limited data about long-term oncologic safety of this procedure. STUDY DESIGN: We reviewed oncologic outcomes of consecutive therapeutic NSM at a single institution. Nipple-sparing mastectomy was offered to patients with no radiologic or clinical evidence of nipple involvement. RESULTS: There were 2,182 NSM performed from 2007 to 2016. Long-term outcomes were assessed in the 311 NSM performed in 2007 to 2012 for Stages 0 to 3 breast cancer; 240 (77%) NSM were for invasive cancer and 71 (23%) were for ductal carcinoma in situ. At 51 months median follow-up, 17 patients developed a recurrence of their cancer. Estimated disease-free survival was 95.7% at 3 years and 92.3% at 5 years. There were 11 (3.7%) locoregional recurrences and 8 (2.7%) distant recurrences; 2 patients had simultaneous locoregional and distant recurrences. There were 2 breast cancer-related deaths in patients with isolated distant recurrences. No patient in the entire 2,182 NSM cohort has had a recurrence in the retained nipple-areola complex. CONCLUSIONS: Rates of locoregional and distant recurrence are acceptably low after nipple-sparing mastectomy in patients with breast cancer. No patient in our series has had a recurrence involving the retained nipple areola complex.

1 March 2019 in Annals of Surgery
Verified
Journal Article
Closed access
PDF file
WLWhitney O. Lane
Whitney O. Lane
STSamantha M. Thomas
Samantha M. Thomas
RBRachel C. Blitzblau
Rachel C. Blitzblau
JPJennifer Kay Plichta
Jennifer Kay Plichta
LRLaura H. Rosenberger
Laura H. Rosenberger
RGRachel A. Greenup
Rachel A. Greenup
Objective: We evaluated patterns of surgical care and their association with overall survival among a contemporary cohort of women with stage IV breast cancer. Background: Surgical resection of the primary tumor remains controversial among women with stage IV breast cancer. Methods: Women diagnosed with clinical stage IV breast cancer from 2003 to 2012 were identified from the American College of Surgeons National Cancer Database. Those with intact primary tumors who were alive 12 months after diagnosis were categorized by treatment sequence: (1) surgery before systemic therapy, (2) systemic therapy before surgery, and (3) systemic therapy alone. Multivariate logistic regression was used to estimate the association of treatment sequence with surgery type. Overall survival was estimated using multivariate Cox proportional hazards models. Results: Among 24,015 women, 56.2% (13,505) underwent systemic therapy alone and 43.8% (10,510) underwent surgical resection. Rates of surgery decreased slightly over time (43.1% in 2003 to 41.9% in 2011). Treatment with systemic therapy before surgery was associated with larger tumor size (median 4.5 vs 3.1 cm, P < 0.001) and receipt of mastectomy (81.4% vs 52.2%, P < 0.001) when compared to those who underwent surgery first. Receipt of surgery, whether before or after systemic therapy (Hazard Ratio, 0.68; 95% confidence interval, 0.62–0.73; Hazard Ratio, 0.56; 95% confidence interval, 0.52–0.61; P < 0.001), was independently associated with improved adjusted overall survival when compared to systemic therapy alone. Conclusions: Surgical resection of the primary tumor occurs in almost half of women with stage IV breast cancer alive 1 year after diagnosis, and is increasingly occurring after systemic therapy. Coordinated multidisciplinary care remains highly relevant in the setting of metastatic breast cancer, where surgical decisions should be made on an individual basis and may affect survival in select women.

31 May 2018 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
COCecilia T. Ong
Cecilia T. Ong
BCBrittany M. Campbell
Brittany M. Campbell
STSamantha M. Thomas
Samantha M. Thomas
RGRachel A. Greenup
Rachel A. Greenup
JPJennifer Kay Plichta
Jennifer Kay Plichta
OFOluwadamilola M. Fayanju
Oluwadamilola M. Fayanju